Holen Sie sich die Stockscreener-App
28.16
0.64%
0.1901
Schlusskurs vom Vortag:
$27.97
Offen:
$27.6
24-Stunden-Volumen:
8.64M
Relative Volume:
0.78
Marktkapitalisierung:
$10.99B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-3.2257
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
+17.00%
1M Leistung:
+14.71%
6M Leistung:
+0.04%
1J Leistung:
-38.34%
1-Tages-Spanne:
$26.89
$28.52
1-Wochen-Bereich:
$23.93
$28.52
52-Wochen-Spanne:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
28.13 | 10.93B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna, Pfizer, and BioNTech stock briefly dips on FDA Covid vaccine probe - Investing.com Canada
FDA Probes If Covid Shots Might Be Linked to Deaths of Adults - Bloomberg.com
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy? - Finviz
Global AI Infrastructure Shift Ignites Biotech Growth Phase - Investing News Network
Ossiam Has $3.08 Million Stake in Moderna, Inc. $MRNA - MarketBeat
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna (MRNA) Just Reclaimed the 200-Day Moving Average - Yahoo Finance
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average - Nasdaq
Invesco Ltd. Has $195.92 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Lido Advisors LLC Sells 140,814 Shares of Moderna, Inc. $MRNA - MarketBeat
Federated Hermes Inc. Acquires 2,251,497 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Daily Commercial
How Recent Shifts Are Changing the Narrative for Moderna Stock - Yahoo Finance
58,854 Shares in Moderna, Inc. $MRNA Bought by Quantbot Technologies LP - MarketBeat
Moderna, Inc. $MRNA Stock Position Lessened by New York State Common Retirement Fund - MarketBeat
Behavioral Patterns of MRNA and Institutional Flows - news.stocktradersdaily.com
Moderna, Inc. (MRNA): A Bull Case Theory - MSN
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates - Victorville Daily Press
Moderna (NASDAQ:MRNA) Shares Up 6.3%Still a Buy? - MarketBeat
Traders Purchase Large Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Finviz
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - MSN
Moderna (MRNA) Recently Broke Out Above the 20-Day Moving Average - Finviz
January 2026 Options Now Available For Moderna (MRNA) - Nasdaq
Skandinaviska Enskilda Banken AB publ Trims Position in Moderna, Inc. $MRNA - MarketBeat
Norges Bank Buys Shares of 3,439,999 Moderna, Inc. $MRNA - MarketBeat
Former FDA commissioners castigate plan to change vaccine approval standards - Seeking Alpha
Moderna to Present at Upcoming Investor Conferences in March 2024 - ACCESS Newswire
Moderna In Crisis? FDA Memo Ties Vaccines To Deaths, Stock Tumbles! - Smartkarma
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Seasonal Vaccines Market Accelerating Growth and Rising Opportunities Through 2035 - GlobeNewswire Inc.
CapEx per share of Moderna, Inc. – DUS:0QF - TradingView
The FDA’s Leaked Covid Memo Is Reckless and Dangerous - Bloomberg.com
Moderna, Inc. $MRNA Shares Sold by Hsbc Holdings PLC - MarketBeat
Goodwin Advises Moderna With Its $1.5 Billion Five-Year Credit Facility From Ares Management - Mondaq
Moderna (MRNA): Reassessing Valuation After FDA Signals Tougher Vaccine Approval Standards - Yahoo Finance
Officer Klinger Acquires 120 Of Moderna Inc [MRNA] - TradingView
Pres Hoge Acquires 336 Of Moderna Inc [MRNA] - TradingView
MVP: Williams & Connolly's David M. Krinsky - Law360
Transcript : Moderna, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 11 - MarketScreener
Moderna (MRNA) Responds to FDA Claims Regarding Vaccine Safety - GuruFocus
Moderna, Inc.: Financial Data Forecasts Estimates and Expectations | 0QF | US60770K1079 - marketscreener.com
Moderna, Inc.: Dividend historical data and projections - marketscreener.com
Prudential Financial Inc. Boosts Stake in Moderna, Inc. $MRNA - MarketBeat
Is Moderna Stock Underperforming the Nasdaq? - Barchart.com
Tougher FDA Rules on Vaccine Approval Might Change the Case for Investing in Moderna (MRNA) - Yahoo Finance
Moderna, Novavax Shares Fall on News FDA Plans to Tighten Vaccine Approvals - The Wall Street Journal
Moderna stock falls after FDA vows to impose new vaccine requirements - The Boston Globe
S&P 500 Gains and Losses Today: Moderna Falls; Synopsys Stock Climbs on Nvidia Partnership - Investopedia
Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10 - Investor's Business Daily
Moderna, Other Pharma Stocks Close Lower After US FDA Reportedly Plans to Toughen Vaccine Approval - marketscreener.com
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):